An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Prime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Prime Medicine, a biotechnology firm focused on innovative genetic therapies, has announced key leadership appointments. Richard Brudnick joins as Chief Business Officer, Niamh Alix as Chief Human Resources Officer, and Fubao Wang, Ph.D., as Senior Vice President, Head of Regulatory. These new executives bring extensive experience in business development, human resources, and regulatory affairs, enhancing the company's capacity to advance its Prime Editing technology. This technology aims to address a broad range of genetic diseases, offering potential one-time curative options.
Positive
The appointment of Richard Brudnick, who has a strong background in business development and leadership in biotechnology.
Niamh Alix's expertise in HR will support team growth and organizational development.
Fubao Wang's extensive regulatory experience is crucial for advancing clinical-stage products.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Prime Medicine, Inc. (“Prime Medicine”), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology, today announced the expansion of the company’s leadership team with the appointments of the following executives:
Richard Brudnick as Chief Business Officer
Niamh Alix as Chief Human Resources Officer
Fubao Wang, Ph.D., as Senior Vice President, Head of Regulatory
“Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission,” said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine. “These esteemed leaders have deep expertise across their respective focus areas, each of which is key to the advancement of our novel Prime Editing technology.”
Richard Brudnick, Chief Business Officer, brings extensive industry experience, including leading successful business development transactions, across multiple stages of development and an array of therapeutic areas. Mr. Brudnick was previously Chief Business Officer and Head of Strategy at Codiak BioSciences and, before that, was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016. Mr. Brudnick joined Bioverativ at the time of its spinoff from Biogen where, over the course of nearly 15 years, he initiated, led and completed numerous transactions, including for several of the company's marketed products and late-stage pipeline, including Tecfidera, Spinraza and its biosimilars joint venture with Samsung. Previously, Mr. Brudnick was the Chief Executive Officer of a regional pharmaceutical distribution business that he sold to a strategic buyer, co-founded two companies, and was a strategy consultant at Bain & Company. Mr. Brudnick earned his undergraduate degree in management science from MIT and his M.S. in management from the Sloan School of Management at MIT.
Niamh Alix, Chief Human Resources (HR) Officer, is a human resources leader who brings nearly 20 years of experience helping to grow teams from small, early-stage organizations to global enterprises. She joins Prime from Orchard Therapeutics, where she was Vice President, Global Talent and HR Business Partner. Prior to that, Ms. Alix held multiple global and regional roles at Lonza, including HR Business Partner for Americas, Mexico, and Canada where she led the HR team and people strategy for a 5,000+ employee population across corporate and manufacturing clients, and across multiple scientific platforms including cell and gene therapy. Prior to that, she held senior HR roles of increasing responsibility at Novartis and Bristol Myers Squibb. She holds a master’s degree in HR strategies from Dublin City University and a B.Sc. in management from the Technological University of Dublin.
Fubao Wang, Ph.D., SVP, Head of Regulatory, has substantial experience leading product development of genomic medicine products, as well as regulatory strategies and execution for both clinical and commercial-stage products. Before Prime, Dr. Wang served as Senior Vice President, Head of Regulatory Affairs at Asklepios BioPharmaceutical where he built and led the regulatory team to support the development of clinical-stage AAV-based gene therapy products. Earlier, he was Vice President, Head of Regulatory CMC at Sarepta Therapeutics, where he supported the development of AAV gene therapy and RNA products, including the FDA approvals of Vyondys and Amondys. He also served as Associate Vice President, U.S. Site Head, CMC Dossiers at Sanofi to support the BLA approval of Dupixent, a monoclonal antibody product. Prior to that, he held a 16-year tenure at Merck serving in research, development and regulatory roles of increasing responsibility, most recently as director, global and emerging markets regulatory affairs, led and contributed to the discovery and development of a variety of vaccine and biologics products. Dr. Wang holds a Ph.D. in molecular biology from Heidelberg University and completed his postdoctoral work in molecular biology at Stanford University.
About Prime Medicine
Prime Medicine, Inc. is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients. For more information, please visit www.primemedicine.com.
What are the recent leadership changes at Prime Medicine?
Prime Medicine appointed Richard Brudnick as Chief Business Officer, Niamh Alix as Chief Human Resources Officer, and Fubao Wang, Ph.D., as Senior Vice President, Head of Regulatory.
How does the new leadership team affect Prime Medicine's strategy?
The new executives bring significant expertise in business development, human resources, and regulatory affairs, enhancing Prime Medicine's ability to advance its Prime Editing technology.
What are the qualifications of the new Chief Business Officer at Prime Medicine?
Richard Brudnick has extensive experience in leading business development transactions across various therapeutic areas and has held significant positions in leading biotechnology firms.
What is Prime Editing technology and its significance?
Prime Editing technology is a precise gene editing approach aimed at addressing a wide spectrum of diseases, with the potential to correct approximately 90% of known disease-causing genetic mutations.
Why is the appointment of Niamh Alix important for Prime Medicine?
Niamh Alix's nearly 20 years of HR experience will help Prime Medicine grow its teams effectively, from early-stage organizations to global enterprises.
